Colgate-Palmolive (CL) officer reports 213-share tax withholding and 76,406 shares held

Rhea-AI Filing Summary

Colgate-Palmolive (CL) reported a routine insider tax-withholding transaction by its Chief Legal Officer and Secretary. On 12/03/2025, the executive had 213 shares of common stock withheld at a price of $78.2 per share, coded as an "F" transaction, which indicates shares were withheld to cover Medicare and income tax obligations on previously granted restricted stock units under the company’s incentive compensation plan.

After this non-open-market transaction, the executive beneficially owns 76,406 shares of Colgate-Palmolive common stock directly and an additional 1,825 shares indirectly through the issuer's 401(k) plan trustee. The filing notes that the restricted stock units themselves continue to be held, reduced only by the amount of shares withheld for taxes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniels Jennifer

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CLO and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		F(1)		213	D	$78.2	76,406	D
Common Stock								1,825	I	By Issuer's 401(k) Plan Trustee

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Payment of Medicare and income tax liability by withholding shares of stock from restricted stock units previously granted under the issuer's incentive compensation plan. The reporting person continues to hold the restricted stock units originally granted, less the amount of this required tax withholding.

	/s/ Kristine Hutchinson, Attorney-in-Fact	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Colgate-Palmolive (CL) report in this Form 4?

The filing reports that Colgate-Palmolive's Chief Legal Officer and Secretary had 213 shares of common stock withheld on 12/03/2025 to cover tax obligations related to restricted stock units.

Was the Colgate-Palmolive (CL) Form 4 transaction an open-market sale?

No. The transaction is coded "F", which reflects payment of Medicare and income tax liability by withholding shares from previously granted restricted stock units, rather than an open-market buy or sell.

How many Colgate-Palmolive (CL) shares does the reporting person own after the transaction?

Following the reported tax-withholding transaction, the executive beneficially owns 76,406 shares directly and 1,825 shares indirectly through the issuer's 401(k) plan trustee.

What price per share was used in the Colgate-Palmolive (CL) tax-withholding transaction?

The 213 shares withheld for tax purposes were valued at a price of $78.2 per share in the reported transaction.

Do the Colgate-Palmolive (CL) restricted stock units remain outstanding after this Form 4 event?

Yes. The explanation states that the reporting person continues to hold the restricted stock units originally granted, reduced only by the amount of shares withheld to satisfy the required tax withholding.

What is the reporting person’s role at Colgate-Palmolive (CL)?

The reporting person is an officer of Colgate-Palmolive, serving as CLO and Secretary, as indicated in the relationship section of the filing.